0;*/ $_t4StyleInternal = $internal; if($_t4StyleInPreview){ $_t4StyleBaseServer = 'https://t4.gla.ac.uk'; } else { $_t4StyleBaseServer = 'http://www.gla.ac.uk'; } if($_SERVER['SERVER_NAME'] == 'udcf.gla.ac.uk') { $_t4StyleBaseServer = 'https://udcf.gla.ac.uk'; } elseif($_SERVER['SERVER_NAME'] == 'www2.gla.ac.uk') { $_t4StyleBaseServer = 'https://www2.gla.ac.uk'; } elseif(($_SERVER['SERVER_NAME'] == 'www.gla.ac.uk')&&($_SERVER['REQUEST_SCHEME'] == 'https')) { $_t4StyleBaseServer = 'https://www.gla.ac.uk'; } ?> edit in t4', $internal); ?>

Professor Jeff Evans

Professor Jeff Evans

‌Director of Institute of Cancer Sciences

‘Our vision is to be in a position to treat cancer patients individually, with customised drugs, targeted treatments and diagnostic options that are less toxic and more effective.’

Professor Jeff Evans’ ground-breaking research in cancer and his management of significant clinical trials are giving cancer patients worldwide new hope, thanks to treatments being tested at Glasgow.

Professor Evans, who is Director of the Institute of Cancer Sciences and lead of the Glasgow Experimental Cancer Medicine Centre, is Professor of Translational Cancer Research.

Currently, he is investigating drugs that could stop pancreatic cancer from spreading; a major problem in this disease. Working with Cancer Research UK (CRUK), Professor Evans is leading a first-of-its-kind pancreatic cancer trial to make cancer cells more responsive to chemotherapy and radiotherapy. Most cancer deaths are caused by the disease spreading, so finding drugs that can slow or halt this process is an important goal for cancer researchers. Professor Evans and his team are researching several new drugs that have the potential to tackle this problem in people with pancreatic cancer.

Find out more about Professor Evans.

Professor Evan’s clinical research interests are in the pre-clinical and clinical development of novel anti-cancer agents including molecular targeted therapies and gene therapy.